Pancreatic Ductal Adenocarcinoma (PDAC)Delivered 2026-05-07

Daraxonrasib in PDAC: Peak Sales Estimate

Independent Revenue Model

Independent bottoms-up peak sales estimate for daraxonrasib in PDAC. Central estimate of $8.5B peak annual global sales, modestly above analyst consensus of $5–7.6B, driven by a 55% peak market share assumption and a $200K annual price benchmark from approved KRAS inhibitor comparables.

Read the full report

Enter your details below to access the complete analysis — clinical timelines, competitive landscape, and analyst commentary.

We won't spam you. Your details are used only to send relevant intelligence updates.

Want a report like this for your target?

We build custom intelligence reports scoped to your therapeutic area, asset, or investment thesis.

Book a Call